PPIDT00356
Drug Information
| Name | Bimekizumab |
|---|---|
| Sequence | EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYNMAWVRQAPGKGLEWVATITYEGRNTYYRDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASPPQYYEGSIYRLWFAHWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| DrugBank_ID | DB12917 |
| Type | biotech |
| Indication | Bimekizumab is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy [L39665] or phototherapy.[L48546, L51053] In Canada, it is also approved for the treatment of active psoriatic arthritis in adults alone or in combination with a conventional non-biologic disease-modifying antirheumatic drug (cDMARD).[L51053] It is also used to treat adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.[L51053] Bimekizumab is also used for the treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).[L51053] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Subcutaneous |
160 mg
|
| Injection, solution | Subcutaneous |
160 mg/1mL
|
| Injection, solution | Subcutaneous |
320 mg/2mL
|
| Injection, solution | Subcutaneous |
320 mg
|
| Solution | Subcutaneous |
160 mg / mL
|
| Solution | Subcutaneous |
160.00 mg
|